Limb Girdle Muscular Dystrophy (LGMD) Market Insights, Epidemiology, and Market Forecast 2030

(Albany, US) DelveInsight ha s launched a new report on Limb Girdle Muscular Dystrophy Market 

DelveInsight’s Limb Girdle Muscular Dystrophy (LGMD) Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Limb Girdle Muscular Dystrophy (LGMD), historical and forecasted epidemiology as well as the LGMD market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Limb Girdle Muscular Dystrophy market report provides current treatment practices, emerging drugs, Limb Girdle Muscular Dystrophy (LGMD) market share of the individual therapies, current and forecasted Limb Girdle Muscular Dystrophy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Limb Girdle Muscular Dystrophy (LGMD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Limb-Girdle Muscular Dystroph market
Limb-Girdle Muscular Dystroph market

Click Here For Free Sample Page:- https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market

KEY FACT FROM THE REPORT

  • According to the National Institutes of Health, it is difficult to determine the prevalence of limb-girdle muscular dystrophy because its features vary and overlap with those of other muscle disorders. Prevalence estimates range from 1 in 14,500 to 1 in 123,000 individuals. 
  • According to the National Organization for Rare Disorders, the incidence of the disorder is unknown. The relative frequencies of the different types of LGMD vary from population to population, but worldwide LGMD2G, 2H and 2J are extremely rare. 
  • As per the Orphanet, the estimated prevalence for all forms of LGMD ranges from 1/44,000 to 1/123,000. 
  • As per the literature analysis, the age of onset varies among the different mutations. It also can vary amongst families and family members with the same mutation. Reported age of onset of LGMDs is between 1 and 50 years, although some patients may be asymptomatic. Myofibrillar myopathies can present in the first decade of life up until the 60s or 70s.

 

MAJOR KEY PLAYERS OF THE REPORT

  • PTC therapeutics
  • Sarepta Pharma Co.
  • aTyr Pharma

 

NAME OF DRUGS COVERED IN THE REPORT

  • SRP-9003
  • Deflazacort

 

Table of content

1. Key Insights

2. Executive Summary of Limb Girdle Muscular Dystrophy (LGMD)

3. Competitive Intelligence Analysis for Limb Girdle Muscular Dystrophy (LGMD)

4. Limb Girdle Muscular Dystrophy (LGMD): Market Overview at a Glance

4.1. Limb Girdle Muscular Dystrophy (LGMD) Total Market Share (%) Distribution in 2017

4.2. Limb Girdle Muscular Dystrophy (LGMD) Total Market Share (%) Distribution in 2030

5. Limb Girdle Muscular Dystrophy (LGMD): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Limb Girdle Muscular Dystrophy (LGMD) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Limb Girdle Muscular Dystrophy (LGMD) Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Limb Girdle Muscular Dystrophy (LGMD) Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Limb Girdle Muscular Dystrophy (LGMD) Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Limb Girdle Muscular Dystrophy (LGMD) Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Limb Girdle Muscular Dystrophy (LGMD) Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Limb Girdle Muscular Dystrophy (LGMD) Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Limb Girdle Muscular Dystrophy (LGMD) Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Limb Girdle Muscular Dystrophy (LGMD) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Limb Girdle Muscular Dystrophy (LGMD) Treatment and Management

8.2. Limb Girdle Muscular Dystrophy (LGMD) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Limb Girdle Muscular Dystrophy (LGMD) Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

13. Limb Girdle Muscular Dystrophy (LGMD): Seven Major Market Analysis

13.1. Key Findings

13.2. Limb Girdle Muscular Dystrophy (LGMD) Market Size in 7MM

13.3. Limb Girdle Muscular Dystrophy (LGMD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Limb Girdle Muscular Dystrophy (LGMD) Total Market Size in the United States

15.1.2. Limb Girdle Muscular Dystrophy (LGMD) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Limb Girdle Muscular Dystrophy (LGMD) Total Market Size in Germany

15.3.2. Limb Girdle Muscular Dystrophy (LGMD) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Limb Girdle Muscular Dystrophy (LGMD) Total Market Size in France

15.4.2. Limb Girdle Muscular Dystrophy (LGMD) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Limb Girdle Muscular Dystrophy (LGMD) Total Market Size in Italy

15.5.2. Limb Girdle Muscular Dystrophy (LGMD) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Limb Girdle Muscular Dystrophy (LGMD) Total Market Size in Spain

15.6.2. Limb Girdle Muscular Dystrophy (LGMD) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Limb Girdle Muscular Dystrophy (LGMD) Total Market Size in the United Kingdom

15.7.2. Limb Girdle Muscular Dystrophy (LGMD) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Limb Girdle Muscular Dystrophy (LGMD) Total Market Size in Japan

15.8.3. Limb Girdle Muscular Dystrophy (LGMD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Limb Girdle Muscular Dystrophy (LGMD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Related Reports

ABOUT DELVEINSIGHT 

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

CONTACT US:

Shruti Thakur
in[email protected]
+91-9650213330
DelveInsight

Related posts